Weight management · Ozempic, Wegovy, Rybelsus
Why Isn't Ozempic or Wegovy Working for Me? The GLP1R Connection
Semaglutide produces 15 to 17 percent average weight loss in trials, but the range between individuals is enormous. A common GLP1R variant shifts both how much you lose and how much nausea you get.
Semaglutide produces an average of 15 to 17 percent body weight loss in clinical trials, but the spread between patients is wide. Some people lose nothing in the first three months. Others lose more than 25 percent. A common GLP1R variant explains a meaningful chunk of that variation in both weight loss and side-effect risk.
15 to 17% average body weight loss in clinical trials, but individual results range from 0 to over 25 percent
Common reasons semaglutide underdelivers
You haven't reached the maintenance dose yet
Semaglutide is titrated slowly to limit nausea. The full Wegovy dose is 2.4 mg weekly, but it takes 16 to 20 weeks of stepping up to get there. Most of the weight loss happens once you're at the maintenance dose, so a flat scale during titration is normal.
Diet, alcohol, and timing
Semaglutide curbs appetite, but it doesn't override deliberate calorie intake. Liquid calories (alcohol, sugary drinks, smoothies) bypass the satiety effect almost entirely. Late-evening eating windows, when GLP-1 levels naturally fall, also blunt the response.
Other medications and conditions
Steroids, some antidepressants, and antipsychotics can drive weight gain that offsets the GLP-1 effect. Untreated hypothyroidism, PCOS, and Cushing's syndrome are also common confounders.
How your genetics can play a role
GLP1R codes for the GLP-1 receptor, the direct target of semaglutide. A single common SNP in the signal peptide (rs10305420, called Pro7Leu) changes how efficiently the receptor gets to the cell surface. Note that there are no established pharmacogenetic dosing guidelines for semaglutide,[1] and GLP1R status does not determine whether the drug will work for you.
| Gene | What it affects |
|---|---|
| GLP1R | The Leu7 allele changes a single amino acid in the signal peptide that guides the GLP-1 receptor to the cell membrane. Carriers of one or two Leu7 alleles tend to have a stronger response to semaglutide. They also have a higher rate of nausea and vomiting. That fits the model that more receptor signal means both more weight loss and more side effects. |
Roughly a third of people of European descent carry at least one Leu7 allele. Heterozygotes (Pro7/Leu7) lose about 0.76 kg more weight than non-carriers. Homozygotes (Leu7/Leu7) lose about 1.5 kg more. The variant doesn't determine whether semaglutide will work for you. It shifts the size of the typical response and tilts the side-effect profile.
Want to know what your genetics say about how you'll respond to Semaglutide?
A Gene2Rx report reads your own DNA to show how it may affect your response to Semaglutide and your other medications.
Find out todayWhen to consider pharmacogenetic testing
Pharmacogenetic testing is most useful if you've been on the maintenance dose of semaglutide for 8 to 12 weeks with little weight loss, or if nausea has been severe enough that you're thinking about stopping. Knowing your GLP1R status helps set realistic expectations and informs the call to try a different drug in the class.
What you can do next
- Confirm you've actually reached and stayed at the maintenance dose for at least 8 to 12 weeks. Most weight loss is in the maintenance phase, not titration.
- Track liquid calories and late-evening eating. Both can wipe out a meaningful chunk of the satiety effect.
- Review your other medications with your prescriber, especially anything with weight-gain side effects.
- Talk to your doctor about whether tirzepatide (Mounjaro / Zepbound) is a reasonable next step. Tirzepatide adds GIP-receptor activity and tends to produce more weight loss in trials, though it has its own pharmacogenetic considerations.
Related medications
Related guides
- Tirzepatide (Mounjaro, Zepbound) Not Working: GLP1R and GIPR Genetics
- Retatrutide Pharmacogenetics: Triple Agonist Genetics (Investigational)
- Acid Reflux Medication Not Working? Your Genetics May Be Why
- ADHD Medication Not Working? What Your DNA Might Have to Do With It
- Allopurinol Not Working for Gout? ABCG2 Pharmacogenetics Explained
- Amitriptyline Not Working for Migraines? Genetics May Be Why
Frequently asked questions
Will my response to tirzepatide be the same as my response to semaglutide?
Probably not, because tirzepatide hits both the GLP-1 and GIP receptors. The GLP1R variant that affects semaglutide also affects tirzepatide's GLP-1 arm, but tirzepatide is also sensitive to a separate GIPR variant that doesn't apply to semaglutide. People who can't tolerate one are sometimes fine on the other.
Does the GLP1R variant mean I shouldn't take semaglutide?
No. The variant predicts the size and tilt of the response, not whether the drug will work. Most carriers of the Leu7 allele do well on semaglutide and many lose more weight than average. The information is most useful for setting expectations and deciding whether a slower titration makes sense.
If I'm not losing weight, should I just go up to a higher dose?
If you tolerate the current dose, escalating per the standard schedule is the right next step. If you're already at the maximum approved dose without effect, switching drug class is a more productive move than pushing the dose further off-label.
References
- PharmGKB / Stanford University. PharmGKB: The Pharmacogenomics Knowledge Base. pharmgkb.org
Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your medication. Never stop or change a medication without medical supervision.